Printer Friendly

QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA

 QUADRA LOGIC BEGINS SKIN CANCER TRIALS OF NEW DRUG IN CANADA
 VANCOUVER, British Columbia, Oct. 30 /PRNewswire/ -- Quadra Logic Technologies Inc. (Toronto, Vancouver: QLT) announced today that a clinical trial of the company's light-activated drug, Benzoporphyrin derivative (BPD), has commenced in Canada.
 The clinical trial, which is being conducted by medical specialists at the British Columbia Cancer Agency, is designed to test the safety and efficacy of BPD as a potential treatment for non-melanoma skin cancer.
 Patients suffering from malignant skin lesions will be injected intravenously with the drug. After intraveneous administration BPD circulates and accumulates in cancerous cells. Unlike most other anti-cancer drugs, BPD has no effect on cancerous cells until it is "switched-on" by light.
 After a three- to four-hour waiting period the cancer is exposed to light from a medical laser to activate the drug. The treatment takes between five minutes and 20 minutes depending on the desired amount of light to be delivered. The process of treating disease conditions in this manner with light-activated drugs is known as Photodynamic Therapy or PDT.
 The clinical trial in Vancouver will provide additional data on BPD and serve to complement a clinical trial underway at the Massachusetts General Hospital (MGH) in Boston. Preliminary results from the Boston clinical trial, which also involves patients with malignant skin lesions, are encouraging, and patients receiving BPD have not experienced any prolonged skin sensitivity to bright light, the most notable side-effect of PDT.
 "The goal of this study is to ensure that the drug is safe and to obtain preliminary information on the effectiveness of the therapy," says Dr. Harvey Lui, a dermatologist and laser surgery specialist with the University of British Columbia Division of Dermatology.
 Lui was formerly an investigator at the Massachusetts General Hospital and is now heading the BPD trials in Vancouver. Lui says additional clinical studies will be needed to determine whether BPD removes skin tumors as effectively as existing treatments.
 "If you have a single skin cancer tumor on your arm, surgery is probably the simplest and most straight-forward treatment. But suppose you are prone to basal cell cancers and every year you have several of them. With surgery, you would have to undergo multiple operations every year.
 "By contrast, using BPD and photodynamic therapy allows a physician to treat several tumors at once, and doesn't usually leave large, disfiguring scars. The cosmetic effects of the treatments are quite good compared to surgery."
 Although BPD is currently administered to patients intravenously, QLT is also studying new formulations such as topical preparations of the drug.
 First identified by researchers at Quadra Logic and the University of British Columbia, BPD is one of only a few drugs to be both discovered and developed in Canada.
 Quadra Logic Technologies Inc., is a pharmaceutical corporation engaged in the research, development and commercialization of photosensitive drugs for the treatment and prevention of disease.
 -0- 10/30/92
 /CONTACT: David J. Main, manager of investor relations of Quadra Logic, 604-872-7881 or 800-663-5486/
 (QLT.) CO: Quadra Logic Technologies Inc. ST: British Columbia IN: MTC SU:


JB -- LA006 -- 6952 10/30/92 08:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 30, 1992
Words:519
Previous Article:APPLE COMPUTER ANNOUNCES NEW PROGRAM FOR MULTIMEDIA DEVELOPERS AT THE '92 MACROMEDIA CONFERENCE
Next Article:ONCOR, INCORPORATED ANNOUNCES EUROPEAN PARTNERSHIP WITH AMERSHAM INTERNATIONAL
Topics:


Related Articles
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
BIOMIRA INC. ANNOUNCES RESULTS OF PHASE I CLINICAL TRIALS OF ITS THERATOPE PRODUCTS
QUADRA LOGIC BEGINS BOSTON CLINICAL TRIAL OF NEW DRUG AS A POTENTIAL TREATMENT FOR PSORIASIS
QUADRA LOGIC TECHNOLOGIES INC. ANNOUNCES RESULTS OF TESTS
HYAL ANNOUNCES SECOND PHASE III CLINICAL TRIAL FOR TOPICAL PAIN PRODUCT
QLT RECEIVES FIRST EUROPEAN APPROVAL FOR PHOTOFRIN(R); HOLLAND APPROVAL EXPANDS USE TO LUNG AND ESOPHAGEAL CANCERS
QUADRA LOGIC RECEIVES JAPANESE APPROVAL FOR PHOTOFRIN(R)
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF PHOTOFRIN(R)
QLT PHOTOTHERAPEUTICS INC. ANNOUNCES CANADIAN HEALTH PROTECTION BRANCH APPROVES PHOTOFRIN(R) FOR TREATMENT OF ESOPHAGEAL CANCER
TAXOTERE(R) (docetaxel) APPROVED IN CANADA FOR TREATMENT OF ADVANCED BREAST AND NON-SMALL CELL LUNG CANCER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters